25332-39-2 Usage
Description
Trazodone Hydrochloride belongs to the hydrochloride salt form of trazodone with antidepressant and sedative activities, which is primarily used in the treatment of major depression. It serves as a serotonin uptake inhibitor that is effective for patients suffering from major depressive disorders and other subsets of depressive disorders, which is especially helpful for geriatric patients with severe agitation and certain depressive disorders associated with insomnia and anxiety since it has proved that trazodone also has anti-anxiety (anxiolytic) and sleep-inducing (hypnotic) effects. Besides, it is often prescribed as a sedative that is used for the treatment of panic attacks, aggressive behavior, agoraphobia, and cocaine withdrawal in combination with other drugs. Trazodone Hydrochloride is an oral drug that functions by affecting the balance of chemicals (neurotransmitters) within the brain that nerves use to communicate with (stimulate) each other.
References
https://en.wikipedia.org/wiki/Trazodone
http://www.medicinenet.com/trazodone/article.htm
https://www.drugbank.ca/drugs/DB00656
http://bodyandhealth.canada.com/drug/getdrug/ratio-trazodone
https://pubchem.ncbi.nlm.nih.gov/compound/62935#section=Top
Chemical Properties
White to Off-White Solid
Uses
Different sources of media describe the Uses of 25332-39-2 differently. You can refer to the following data:
1. A serotonin uptake inhibitor
2. antihistamine
3. Monoamine reuptake inhibitor; antidepressant.
Definition
ChEBI: A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.
Therapeutic Function
Tranquilizer
General Description
Trazodone is a antidepressant drug sold under trade names such as Desyrel? and Oleptro? for treatment of anxiety disorder, depression, and insomnia. Trazadone, a serotonin antagonist and reuptake inhibitor (SARI), also has anti-anxiety and hypnotic effects. This certified Snap-N-Spike? solution is suitable for use in clinical toxicology, forensic analysis, or urine drug testing methods by LC-MS/MS or GC/MS.
Biochem/physiol Actions
Antidepressant that potentiates the activity of serotonin uptake blockers and has full 5-HT2C serotonin receptor agonist activity. It is metabolized to the 5-HT1 serotonin receptor agonist 1-(3-Chlorophenyl)piperazine.
Clinical Use
Tricyclic-related antidepressant
Drug interactions
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effects.
Antidepressants: avoid concomitant use with
MAOIs and moclobemide.
Antiepileptics: antagonism of anticonvulsant effect;
concentration reduced by carbamazepine.
Antimalarials: manufacturer advises avoid
concomitant use with artemether and lumefantrine
and piperaquine with artenimol.
Antivirals: concentration increased by ritonavir;
increased risk of ventricular arrhythmias with
saquinavir - avoid; concentration possibly increased
by telaprevir.
Metabolism
Trazodone is hepatically metabolised via the cytochrome P450 isoenzyme CYP3A4 by n-oxidation and hydroxylation. The metabolite m-chlorophenylpiperazine is active. Trazodone is excreted in the urine almost entirely in the form of its metabolites.
Check Digit Verification of cas no
The CAS Registry Mumber 25332-39-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,3,3 and 2 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 25332-39:
(7*2)+(6*5)+(5*3)+(4*3)+(3*2)+(2*3)+(1*9)=92
92 % 10 = 2
So 25332-39-2 is a valid CAS Registry Number.
InChI:InChI=1/C19H22ClN5O.ClH/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25;/h1-3,5-7,9,15H,4,8,10-14H2;1H
25332-39-2Relevant articles and documents
CONTINUOUS PROCESS FOR THE PREPARATION OF TRAZODONE
-
, (2019/08/29)
The present invention relates to an improved process for the preparation of trazodone. In particular, the present invention relates to a continuous process for the preparation of trazodone. More in particular, the present invention relates to a new method for the preparation of trazodone, said method comprising at least one step consisting of a continuous process performed in a flow reactor.
Preparation method of trazodone hydrochloride
-
Paragraph 0046; 0047, (2016/12/01)
The invention is applicable to the field of chemistry and chemical engineering and provides a preparation method of trazodone hydrochloride. The preparation method comprises the following steps: mixing N-(3-chloro-phenyl)-N'-(3-chloropropyl)-piperazine hydrochloride and 1,2,4-triazolo[4,3-a]pyridin-3(2H)-one in a solvent; adding an alkali, and heating and reflowing; carrying out heat filtering into a reaction system, adding alkali liquid and heating and reflowing again in sequence; crystallizing to obtain trazodone; taking the trazodone to react with hydrochloric acid to obtain the trazodone hydrochloride. According to the preparation method of the trazodone hydrochloride, provided by the invention, the total yield of the product is improved, and the content of an impurity N-(3-chloro-phenyl)-N'-(3-chloropropyl)-piperazine is remarkably reduced, so that the industry limitation requirements can be directly met. The preparation method has simple flow steps so that the production cost is reduced; the process is stable and industrial production can be carried out.
TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM
-
Page/Page column 13-16, (2009/04/25)
A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature o at least 40°C for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.
